{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:29:44Z","timestamp":1790627384139,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1888-1","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T23:40:13Z","timestamp":1476142813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study"],"prefix":"10.1186","volume":"16","author":[{"given":"Philippa C.","family":"Matthews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda K.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Stoesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Scarborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"issue":"1","key":"1888_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","volume":"28","author":"B Foxman","year":"2014","unstructured":"Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1\u201313.","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"1888_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269\u201384.","journal-title":"Nat Rev Microbiol"},{"key":"1888_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fmicb.2014.00551","volume":"5","author":"N Cassir","year":"2014","unstructured":"Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol. 2014;5:551.","journal-title":"Front Microbiol"},{"issue":"3","key":"1888_CR4","doi-asserted-by":"publisher","first-page":"e007363","DOI":"10.1136\/bmjopen-2014-007363","volume":"5","author":"C Rosso-Fernandez","year":"2015","unstructured":"Rosso-Fernandez C, Sojo-Dorado J, Barriga A, Lavin-Alconero L, Palacios Z, Lopez-Hernandez I, Merino V, Camean M, Pascual A, Rodriguez-Bano J, et al. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015;5(3):e007363.","journal-title":"BMJ Open"},{"issue":"16","key":"1888_CR5","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/jama.2014.12842","volume":"312","author":"L Grigoryan","year":"2014","unstructured":"Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. Jama. 2014;312(16):1677\u201384.","journal-title":"Jama"},{"issue":"4","key":"1888_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","volume":"39","author":"S Meier","year":"2011","unstructured":"Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39(4):333\u201340.","journal-title":"Infection"},{"issue":"8","key":"1888_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/phar.1434","volume":"34","author":"JL Reffert","year":"2014","unstructured":"Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2014;34(8):845\u201357.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"1888_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10156-007-0534-7","volume":"13","author":"T Mikuniya","year":"2007","unstructured":"Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K, Kariyama R, Kumon H. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother. 2007;13(5):285\u201390.","journal-title":"J Infect Chemother"},{"issue":"1","key":"1888_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/0974-7796.148585","volume":"7","author":"A Sultan","year":"2015","unstructured":"Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan HM. Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urology annals. 2015;7(1):26\u201330.","journal-title":"Urology annals"},{"issue":"1","key":"1888_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","volume":"29","author":"H Pullukcu","year":"2007","unstructured":"Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007;29(1):62\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"1888_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","volume":"22","author":"S Senol","year":"2010","unstructured":"Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, Arda B, Ulusoy S. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 2010;22(5):355\u20137.","journal-title":"J Chemother"},{"issue":"12","key":"1888_CR12","doi-asserted-by":"publisher","first-page":"e004157","DOI":"10.1136\/bmjopen-2013-004157","volume":"3","author":"LD Qiao","year":"2013","unstructured":"Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, Yang B, Niu YJ, Wang Y, Shi BK, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open. 2013;3(12):e004157.","journal-title":"BMJ Open"},{"key":"1888_CR13","unstructured":"National Institute of Health and Care Excellence: Fosfomycin for treating urinary tract infections caused by bacteria that are resistant to more than one antibiotic [\n                    https:\/\/www.nice.org.uk\/guidance\/esuom17\/resources\/fosfomycin-for-treating-urinary-tract-infections-caused-by-bacteria-that-are-resistant-to-more-than-one-antibiotic-17481397957\n                    \n                  ]. Accessed Sept 2015."},{"key":"1888_CR14","unstructured":"National Institute of Health and Care Excellence Evidence Summary: Unlicensed or off-label medicine. Multidrug resistant urinary tract infections: fosfomycin trometamol (NICE advice [ESUOM17]) [\n                    https:\/\/www.nice.org.uk\/advice\/esuom17\/chapter\/key-points-from-the-evidence\n                    \n                  ]. Accessed Sept 2015."},{"key":"1888_CR15","unstructured":"Public Health England: Management of infection guidance for primary care for consultation and local adaptation [\n                    https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/524984\/Management_of_infection_guidance_for_primary_care_for_consultation_and_local_adaptation.pdf\n                    \n                  ]. Accessed Sept 2015."},{"key":"1888_CR16","unstructured":"European Association of Urology Guidelines on Urological Infections [\n                    http:\/\/uroweb.org\/wp-content\/uploads\/18_Urological-infections_LR.pdf\n                    \n                  ]. Accessed Sept 2015."},{"issue":"10","key":"1888_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.acuro.2014.05.004","volume":"38","author":"A Garcia-Tello","year":"2014","unstructured":"Garcia-Tello A, Gimbernat H, Redondo C, Arana DM, Cacho J, Angulo JC. Extended-spectrum beta-lactamases in urinary tract infections caused by Enterobacteria: understanding and guidelines for action. Actas Urol Esp. 2014;38(10):678\u201384.","journal-title":"Actas Urol Esp"},{"issue":"7","key":"1888_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1086\/527442","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069\u201377.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1888_CR19","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1128\/AAC.00402-12","volume":"56","author":"EA Neuner","year":"2012","unstructured":"Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56(11):5744\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1888_CR20","unstructured":"British National Formulary [\n                    https:\/\/www.bnf.org\/\n                    \n                  ]. Accessed Sept 2015."},{"issue":"2","key":"1888_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/jac\/dkr466","volume":"67","author":"DE Karageorgopoulos","year":"2012","unstructured":"Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67(2):255\u201368.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1888_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/cid\/civ436","volume":"61","author":"ML Grayson","year":"2015","unstructured":"Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, Gardiner BJ, Frauman AG. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs. Clin Infect Dis. 2015;61(7):1141\u20133.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"1888_CR23","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","volume":"168","author":"J Rodriguez-Bano","year":"2008","unstructured":"Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tortola T, Mirelis B, Navarro G, Cuenca M, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168(17):1897\u2013902.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1888_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/QCO.0000000000000228","volume":"29","author":"Z Tandogdu","year":"2016","unstructured":"Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73\u20139.","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"1888_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","volume":"37","author":"DM Livermore","year":"2011","unstructured":"Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"1888_CR26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s11255-015-1018-9","volume":"47","author":"YH Cho","year":"2015","unstructured":"Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015;47(7):1059\u201366.","journal-title":"Int Urol Nephrol"},{"key":"1888_CR27","first-page":"37","volume":"12","author":"C Tung","year":"2012","unstructured":"Tung C, Cheon C. Single-dose Fosfomycin Tromethamine for Treatment of Urinary Tract Infection In Hong Kong Women: a Preliminary Prospective Study. Hong Kong J Gynaecol Obstet Midwifery. 2012;12:37\u201342.","journal-title":"Hong Kong J Gynaecol Obstet Midwifery"},{"issue":"3","key":"1888_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/jac\/dkt404","volume":"69","author":"F Jansaker","year":"2014","unstructured":"Jansaker F, Frimodt-Moller N, Sjogren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother. 2014;69(3):769\u201372.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1888_CR29","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1128\/AAC.02611-15","volume":"60","author":"I Los-Arcos","year":"2015","unstructured":"Los-Arcos I, Pigrau C, Rodriguez-Pardo D, Fernandez-Hidalgo N, Andreu A, Larrosa N, Almirante B. Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. Antimicrob Agents Chemother. 2015;60(3):1854\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1888_CR30","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/jac\/dkq346","volume":"65","author":"J Oteo","year":"2010","unstructured":"Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernandez S, Lazaro E, de Abajo FJ, Campos J, Spanish E-E-NSG. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010;65(11):2459\u201363.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1888_CR31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajic.2014.06.013","volume":"42","author":"A Sorlozano","year":"2014","unstructured":"Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C, Navarro-Mari JM, Gutierrez-Fernandez J. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control. 2014;42(10):1033\u20138.","journal-title":"Am J Infect Control"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-016-1888-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T18:57:22Z","timestamp":1487703442000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1888-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1888-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]},"article-number":"556"}}